Report of Foreign Issuer (6-k)
August 01 2017 - 7:29AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under
the Securities Exchange Act of 1934
For
the Month of August 2017
001-36203
(Commission
File Number)
CAN-FITE
BIOPHARMA LTD.
(Exact
name of Registrant as specified in its charter)
10
Bareket Street
Kiryat
Matalon, P.O. Box 7537
Petach-Tikva
4951778, Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover
Form 20-F
or Form 40-F.
Form 20-F
þ
Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T
Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T
Rule 101(b)(7): ____
This
Report on Form 6-K (including exhibits thereto) is hereby incorporated by reference into the registrant's Registration Statements
on Form F-3 (File Nos. 333-195124, 333-199033, 333-204795, and 333-209037), to be a part thereof from the date on which this report
is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
On
August 1, 2017, an Annual General Meeting of Shareholders of Can-fite BioPharma Ltd. (the “Company”) approved each
of the seven proposals brought before the Company’s shareholders at the meeting, in accordance with the majority required
for each proposal. Each of those proposals was described in the Company’s Notice of 2017 Annual General Meeting of Shareholders,
dated June 19, 2017, and in its Proxy Statement, dated June 19, 2017, attached as Exhibit 99.1 to the Company’s Form 6-K
that was furnished to the U.S. Securities and Exchange Commission on June 19, 2017.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
Can-Fite
BioPharma Ltd.
|
|
|
|
Date: August 1, 2017
|
By:
|
/s/
Pnina Fishman
|
|
|
Pnina Fishman
|
|
|
Chief Executive Officer
|
3
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Apr 2023 to Apr 2024